Financhill
Buy
58

AZN Quote, Financials, Valuation and Earnings

Last price:
$73.00
Seasonality move :
3.56%
Day range:
$72.41 - $73.39
52-week range:
$61.24 - $87.68
Dividend yield:
2.12%
P/E ratio:
29.32x
P/S ratio:
4.15x
P/B ratio:
5.52x
Volume:
3.6M
Avg. volume:
5.2M
1-year change:
-8.77%
Market cap:
$226.3B
Revenue:
$54.1B
EPS (TTM):
$2.49

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AZN
AstraZeneca PLC
$13.7B $1.12 8.83% 84.16% $84.18
AMGN
Amgen
$8B $4.26 5.67% 279.07% $314.70
BNTX
BioNTech SE
$183.4M -$2.66 17.63% -35.99% $133.41
GILD
Gilead Sciences
$6.8B $1.77 -0.13% 51.38% $115.42
GSK
GSK PLC
$10B $1.04 5.94% 60.08% $41.54
MRNA
Moderna
$115.3M -$3.11 -49.84% -11.55% $47.70
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AZN
AstraZeneca PLC
$73.00 $84.18 $226.3B 29.32x $1.05 2.12% 4.15x
AMGN
Amgen
$287.01 $314.70 $154.3B 26.19x $2.38 3.23% 4.55x
BNTX
BioNTech SE
$111.15 $133.41 $26.7B 191.55x $0.00 0% 9.01x
GILD
Gilead Sciences
$109.02 $115.42 $135.6B 22.95x $0.79 2.84% 4.78x
GSK
GSK PLC
$40.80 $41.54 $82.9B 21.16x $0.43 3.92% 2.10x
MRNA
Moderna
$27.81 $47.70 $10.8B -- $0.00 0% 3.45x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AZN
AstraZeneca PLC
42.02% 0.266 13.05% 0.69x
AMGN
Amgen
90.24% -0.159 34.26% 0.74x
BNTX
BioNTech SE
1.53% 1.010 1.45% 9.86x
GILD
Gilead Sciences
56.56% 0.302 17.9% 1.00x
GSK
GSK PLC
56.56% -0.335 30.39% 0.58x
MRNA
Moderna
-- -0.658 -- 3.92x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AZN
AstraZeneca PLC
$11.3B $3.7B 10.93% 19.55% 27.61% $2.7B
AMGN
Amgen
$5.2B $1.2B 8.85% 97.08% 33.08% $980M
BNTX
BioNTech SE
$104.2M -$562M -3.86% -3.91% -225.11% -$1.5B
GILD
Gilead Sciences
$5.1B $2.5B 13.82% 32.29% 28.63% $1.7B
GSK
GSK PLC
$7B $2.8B 10.19% 23.08% 30.2% $877.6M
MRNA
Moderna
$17M -$1.1B -29.23% -29.23% -900% -$1.2B

AstraZeneca PLC vs. Competitors

  • Which has Higher Returns AZN or AMGN?

    Amgen has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 21.23%. AstraZeneca PLC's return on equity of 19.55% beat Amgen's return on equity of 97.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    AZN
    AstraZeneca PLC
    83.51% $0.94 $70.9B
    AMGN
    Amgen
    63.58% $3.20 $63.6B
  • What do Analysts Say About AZN or AMGN?

    AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 15.32%. On the other hand Amgen has an analysts' consensus of $314.70 which suggests that it could grow by 9.65%. Given that AstraZeneca PLC has higher upside potential than Amgen, analysts believe AstraZeneca PLC is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AZN
    AstraZeneca PLC
    6 2 0
    AMGN
    Amgen
    10 14 2
  • Is AZN or AMGN More Risky?

    AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison Amgen has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.15%.

  • Which is a Better Dividend Stock AZN or AMGN?

    AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. Amgen offers a yield of 3.23% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

  • Which has Better Financial Ratios AZN or AMGN?

    AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Amgen quarterly revenues of $8.1B. AstraZeneca PLC's net income of $2.9B is higher than Amgen's net income of $1.7B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.32x while Amgen's PE ratio is 26.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.15x versus 4.55x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AZN
    AstraZeneca PLC
    4.15x 29.32x $13.6B $2.9B
    AMGN
    Amgen
    4.55x 26.19x $8.1B $1.7B
  • Which has Higher Returns AZN or BNTX?

    BioNTech SE has a net margin of 21.46% compared to AstraZeneca PLC's net margin of -227.46%. AstraZeneca PLC's return on equity of 19.55% beat BioNTech SE's return on equity of -3.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    AZN
    AstraZeneca PLC
    83.51% $0.94 $70.9B
    BNTX
    BioNTech SE
    54.16% -$1.82 $20.8B
  • What do Analysts Say About AZN or BNTX?

    AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 15.32%. On the other hand BioNTech SE has an analysts' consensus of $133.41 which suggests that it could grow by 20.04%. Given that BioNTech SE has higher upside potential than AstraZeneca PLC, analysts believe BioNTech SE is more attractive than AstraZeneca PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    AZN
    AstraZeneca PLC
    6 2 0
    BNTX
    BioNTech SE
    14 5 0
  • Is AZN or BNTX More Risky?

    AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.759%.

  • Which is a Better Dividend Stock AZN or BNTX?

    AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios AZN or BNTX?

    AstraZeneca PLC quarterly revenues are $13.6B, which are larger than BioNTech SE quarterly revenues of $192.3M. AstraZeneca PLC's net income of $2.9B is higher than BioNTech SE's net income of -$437.5M. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.32x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.15x versus 9.01x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AZN
    AstraZeneca PLC
    4.15x 29.32x $13.6B $2.9B
    BNTX
    BioNTech SE
    9.01x 191.55x $192.3M -$437.5M
  • Which has Higher Returns AZN or GILD?

    Gilead Sciences has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 19.72%. AstraZeneca PLC's return on equity of 19.55% beat Gilead Sciences's return on equity of 32.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    AZN
    AstraZeneca PLC
    83.51% $0.94 $70.9B
    GILD
    Gilead Sciences
    76.9% $1.04 $44B
  • What do Analysts Say About AZN or GILD?

    AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 15.32%. On the other hand Gilead Sciences has an analysts' consensus of $115.42 which suggests that it could grow by 5.87%. Given that AstraZeneca PLC has higher upside potential than Gilead Sciences, analysts believe AstraZeneca PLC is more attractive than Gilead Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    AZN
    AstraZeneca PLC
    6 2 0
    GILD
    Gilead Sciences
    15 11 0
  • Is AZN or GILD More Risky?

    AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.86%.

  • Which is a Better Dividend Stock AZN or GILD?

    AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. Gilead Sciences offers a yield of 2.84% to investors and pays a quarterly dividend of $0.79 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

  • Which has Better Financial Ratios AZN or GILD?

    AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Gilead Sciences quarterly revenues of $6.7B. AstraZeneca PLC's net income of $2.9B is higher than Gilead Sciences's net income of $1.3B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.32x while Gilead Sciences's PE ratio is 22.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.15x versus 4.78x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AZN
    AstraZeneca PLC
    4.15x 29.32x $13.6B $2.9B
    GILD
    Gilead Sciences
    4.78x 22.95x $6.7B $1.3B
  • Which has Higher Returns AZN or GSK?

    GSK PLC has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 21.61%. AstraZeneca PLC's return on equity of 19.55% beat GSK PLC's return on equity of 23.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    AZN
    AstraZeneca PLC
    83.51% $0.94 $70.9B
    GSK
    GSK PLC
    74.23% $0.99 $41.5B
  • What do Analysts Say About AZN or GSK?

    AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 15.32%. On the other hand GSK PLC has an analysts' consensus of $41.54 which suggests that it could grow by 1.8%. Given that AstraZeneca PLC has higher upside potential than GSK PLC, analysts believe AstraZeneca PLC is more attractive than GSK PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    AZN
    AstraZeneca PLC
    6 2 0
    GSK
    GSK PLC
    1 5 1
  • Is AZN or GSK More Risky?

    AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.283%.

  • Which is a Better Dividend Stock AZN or GSK?

    AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. GSK PLC offers a yield of 3.92% to investors and pays a quarterly dividend of $0.43 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios AZN or GSK?

    AstraZeneca PLC quarterly revenues are $13.6B, which are larger than GSK PLC quarterly revenues of $9.5B. AstraZeneca PLC's net income of $2.9B is higher than GSK PLC's net income of $2B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.32x while GSK PLC's PE ratio is 21.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.15x versus 2.10x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AZN
    AstraZeneca PLC
    4.15x 29.32x $13.6B $2.9B
    GSK
    GSK PLC
    2.10x 21.16x $9.5B $2B
  • Which has Higher Returns AZN or MRNA?

    Moderna has a net margin of 21.46% compared to AstraZeneca PLC's net margin of -907.48%. AstraZeneca PLC's return on equity of 19.55% beat Moderna's return on equity of -29.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    AZN
    AstraZeneca PLC
    83.51% $0.94 $70.9B
    MRNA
    Moderna
    15.89% -$2.52 $10.1B
  • What do Analysts Say About AZN or MRNA?

    AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 15.32%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 71.51%. Given that Moderna has higher upside potential than AstraZeneca PLC, analysts believe Moderna is more attractive than AstraZeneca PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    AZN
    AstraZeneca PLC
    6 2 0
    MRNA
    Moderna
    5 17 1
  • Is AZN or MRNA More Risky?

    AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

  • Which is a Better Dividend Stock AZN or MRNA?

    AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.12%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios AZN or MRNA?

    AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Moderna quarterly revenues of $107M. AstraZeneca PLC's net income of $2.9B is higher than Moderna's net income of -$971M. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.32x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.15x versus 3.45x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AZN
    AstraZeneca PLC
    4.15x 29.32x $13.6B $2.9B
    MRNA
    Moderna
    3.45x -- $107M -$971M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is It Time to Sell MercadoLibre?
Is It Time to Sell MercadoLibre?

MercadoLibre (NASDAQ:MELI) has earned a reputation for being not dissimilar…

Is Tesla Stock High Risk or High Reward?
Is Tesla Stock High Risk or High Reward?

EV-making supergiant Tesla, Inc. (NASDAQ:TSLA) is going through a difficult…

Why Did Chase Coleman Buy TSM?
Why Did Chase Coleman Buy TSM?

Billionaire Chase Coleman of Tiger Global Management has built a…

Stock Ideas

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 48x

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
80
GWRE alert for Jun 5

Guidewire Software [GWRE] is up 16.33% over the past day.

Buy
60
REVG alert for Jun 5

REV Group [REVG] is up 15.05% over the past day.

Buy
55
SIG alert for Jun 5

Signet Jewelers [SIG] is down 0.96% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock